Market Place
Sourcing Support
Calidi Bio Presents Data on RTNova for Metastatic Lung Cancer
18 Nov 2024 //
GLOBENEWSWIRE
Calidi Closes $7.5M Public Offering of Common Stock
15 Nov 2024 //
GLOBENEWSWIRE
Calidi Biotherapeutics Announces $7.5 Million Public Offering
14 Nov 2024 //
GLOBENEWSWIRE
Calidi Biotherapeutics Announces Proposed Public Offering
13 Nov 2024 //
GLOBENEWSWIRE
Calidi Bio Reports Q3 2024 Operating & Financial Results
12 Nov 2024 //
GLOBENEWSWIRE
Calidi Biotherapeutics To Present RTNova Data At Conferences
24 Oct 2024 //
GLOBENEWSWIRE
Calidi Biotherapeutics Prices $2M Direct Offering
23 Oct 2024 //
GLOBENEWSWIRE
NYSE American Starts Delisting For Calidi Biotherapeutics
18 Oct 2024 //
GLOBENEWSWIRE
Calidi Biotherapeutics Receives FDA Clearance For CLD-101 Trial
30 Sep 2024 //
GLOBENEWSWIRE
Calidi Biotherapeutics Reports Q2 2024 Operating And Financial Results
13 Aug 2024 //
GLOBENEWSWIRE
Calidi Biotherapeutics Launches Nova Cell With $3M Investment
29 Jul 2024 //
GLOBENEWSWIRE
Calidi Biotherapeutics Gets US Patent For SuperNova Technology Platform
18 Jul 2024 //
GLOBENEWSWIRE
Calidi Biotherapeutics Adds Dr. Mark Gilbert To Medical Advisory Board
16 Jul 2024 //
GLOBENEWSWIRE
Calidi to Effect Reverse Stock Split
05 Jul 2024 //
BUSINESSWIRE
Calidi Announces Appointment of Cancer Immunotherapy Pioneer Dr. George BOD
27 Jun 2024 //
BUSINESSWIRE
Calidi Biotherapeutics To Host Live Investor Webinar And Q&A
11 Jun 2024 //
BUSINESSWIRE
Calidi Partners With SIGA For Lung Cancer And Solid Tumor Virotherapy
10 Jun 2024 //
BUSINESSWIRE
Calidi`s CLD-101 Update, RTNova, CLD-201 Preclinical Data At ASCO
03 Jun 2024 //
BUSINESSWIRE
Calidi Exercises Warrants For $2.1M Gross Proceeds
31 May 2024 //
BUSINESSWIRE
Calidi Biotherapeutics Reports Q1 2024 Operating, Financial Results
14 May 2024 //
BUSINESSWIRE
Calidi Bio Presentations At ASCO 2024 Annual Meeting
01 May 2024 //
BUSINESSWIRE
Calidi Biotherapeutics to Host Investor Webinar on April 24
23 Apr 2024 //
BUSINESSWIRE
Calidi Biotherapeutics, Inc. Announces Closing of $6.1 Million Public Offering
19 Apr 2024 //
BUSINESSWIRE
Calidi Reports Fourth Quarter and Full-Year 2023 Operating and Financial Results
15 Mar 2024 //
BUSINESSWIRE
Calidi Biotherapeutics and City of Hope Announce Funding from CIRM
11 Mar 2024 //
BUSINESSWIRE
Calidi to Highlight Novel Systemic Enveloped Oncolytic Virotherapy Platform
12 Feb 2024 //
BUSINESSWIRE
Calidi Biotherapeutics Announces Presentation of Clinical Study for NeuroNova
13 Dec 2023 //
BUSINESSWIRE
Calidi Announces Appointment of David LaPré to its Board of Directors
12 Dec 2023 //
BUSINESSWIRE
Calidi Biotherapeutics Reports Third Quarter 2023 Financial Results
14 Nov 2023 //
BUSINESSWIRE
Calidi Presents Data on CLD-201 Demonstrating Inhibition of Tumor Growth
03 Nov 2023 //
BUSINESSWIRE
Calidi Biot Announces Key Leadership Promotions and New Board Appointment
01 Nov 2023 //
BUSINESSWIRE
Calidi Announces Appointment of Andrew Jackson as Chief Financial Officer
30 Oct 2023 //
BUSINESSWIRE
Calidi To Present Data Highlighting Cell-based Virotherapy Platform Technology
10 Oct 2023 //
BUSINESSWIRE
Calidi Debuts as a Publicly Traded Company Focused on Arming the Immune System
13 Sep 2023 //
BUSINESSWIRE
Calidi goes public via SPAC to push allogeneic cancer therapies
13 Sep 2023 //
FIERCE BIOTECH
Calidi Biotherapeutics to Present at Baird’s Global Healthcare Conference
12 Sep 2023 //
BUSINESSWIRE
Calidi & City of Hope Announce First Patient Dosed in Ph 1 Evaluating CLD-101
18 Jul 2023 //
BUSINESSWIRE
Calidi Biotherapeutics Announces Commitment of $25 Million in Series B Funding
23 Jun 2023 //
BUSINESSWIRE
Oncolytic virus startup Calidi secures $25M toward Series B round
23 Jun 2023 //
ENDPTS
Calidi Receives Funding from the CIRM to Advance SuperNova-1 and NeuroNova-2
13 Dec 2022 //
BUSINESSWIRE
Calidi Biotherapeutics to Present at the 7th Annual Oncolytic Virotherapy Summit
06 Dec 2022 //
BUSINESSWIRE
Calidi Biotherapeutics Presents Promising Data from SuperNova-1 (SNV1)
07 Nov 2022 //
BUSINESSWIRE
Calidi Biotherapeutics to Present SNV1 Data at the 2022 SITC Annual Meeting
12 Oct 2022 //
BUSINESSWIRE
Calidi Appoints David Sans, FAARM, Ph.D., MBA, as Head of Corporate Development
28 Sep 2022 //
BUSINESSWIRE
Calidi Biotherapeutics to Present at Two Upcoming Conferences
08 Sep 2022 //
BUSINESSWIRE
Calidi Biotherapeutics to Present at Jefferies Healthcare Conference
02 Jun 2022 //
BUSINESSWIRE
Calidi Bio Granted U.S. Patent for Proprietary Therapeutic Delivery Platform
24 May 2022 //
BUSINESSWIRE
Calidi Bio Appoints Alfonso "Chito" Zulueta to Its Board of Directors
04 Feb 2022 //
BUSINESSWIRE
Calidi Announces Presentation at 6th Annual Oncolytic Virotherapy Summit
25 Oct 2021 //
BUSINESSWIRE
Calidi Biotherapeutics Announces Exclusive License Agreement with City of Hope
16 Aug 2021 //
BUSINESSWIRE
Calidi Biotherapeutics Announces Agreement with Northwestern University
04 Aug 2021 //
BUSINESSWIRE
Calidi Announces European Patent Granted by EPO
01 Dec 2020 //
BUSINESSWIRE
Calidi Announces FDA Approval for COVID-19 Treatment mfg by Partner
03 Aug 2020 //
BUSINESSWIRE
Calidi Announces Appointment of Jim Schoeneck, Accomplished Biotech
01 Jul 2020 //
BUSINESSWIRE
Calidi Biotherapeutics Announces Two Abstracts Accepted for PPT at AACR 2020
22 Jun 2020 //
BUSINESSWIRE
